A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome

Summary

The purpose of the study is to evaluate efficacy and safety of rozanolixizumab to treat adult study participants with severe fibromyalgia syndrome (FMS).

Timeline

Start

2022-12-21

Primary completion

2024-05-28

Completion

2024-07-09

Outcome

Missed primary endpoint

registry analysis (superiority test); Placebo (PBO) vs RLZ 12 Weeks; p = 0.129 NCT05643794 ↗

Drugs

Indications